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A total of 10–40% of patients with Hodgkin’s disease relapse following initial curative therapy. Intensive follow-up is resource
intensive and may identify false relapses. We performed a retrospective review of all patients with Hodgkin’s disease treated at our
centre between 1990 and 1999 to evaluate the utility of the components of follow-up. A total of 107 patients met the inclusion and
exclusion criteria. The median age was 33 years and the median duration of follow-up 38 months. The total number of follow-up
visits was 1209 and total number of CT scans 283. There were 109 suspected relapses of which 22 proved to be true relapses. Of
the latter, 14 were identified clinically, six radiologically and two via lab testing. The routine CT scan detected only two relapses (9%),
yet accounted for 29% of the total follow-up costs. Based on data from our centre, the cost per true relapse was $6000 US, 49%
incurred by radiological tests. The majority of the cost of follow-up was incurred by routine follow-up (84%) as opposed to the
investigation of suspected relapses (16%). We conclude that most true relapses are clinically symptomatic and that the routine CT is
an expensive and inefficient mode of routine follow-up.
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The majority of patients with Hodgkin’s disease are now cured
with primary therapy (Urba and Longo, 1992). Nevertheless, 10–
15% of patients with localised disease and up to 50% of patients
with advanced stage disease still relapse following initial curative
therapy (Hasenclever and Diehl, 1998). Patients who relapse after
radiation alone can be effectively salvaged with chemotherapy
and a proportion of patients who fail after chemotherapy will be
long-term survivors after stem cell transplantation (Linch et al,
1993).
Given the availability of potentially curative second-line therapy
and the theoretical benefit of early detection and treatment of
Hodgkin’s relapses, most centres have adopted a policy of close
follow-up following curative therapy for Hodgkin’s disease.
However, close follow-up is expensive as well as resource intensive
and it may identify numerous suspected but false relapses, leading
to further testing and heightened patient anxiety.
The follow-up protocols for most clinical trials are based on a
report generated in 1989 by pathologists, radiologists and
oncologists who had gathered in the Cotswolds (Lister et al,
1989). This report recommended that patients be assessed every 3
months during the first 2 years post-therapy, every 4 months
during the third year, every 6 months during the fourth and fifth
years, and annually thereafter. The authors recommended that the
frequency and type of radiological studies reflect the initial sites of
disease, but more specific guidelines were not provided. The
uncertainty about the value of routine radiological investigations
in the detection of relapse has increased after two studies showed
that most relapses are detected as a result of patient-reported
symptoms, not radiological investigations (Radford et al, 1997;
Torrey et al, 1997).
We performed a retrospective review of all adult patients
followed at the Toronto Sunnybrook Regional Cancer Centre
between 1990 and 1999 post curative therapy for Hodgkin’s
disease. The objective of our study was to evaluate the utilities of
the clinical assessments, the radiological tests and the laboratory
tests to detect Hodgkin’s relapses.
METHODS
Inclusion and exclusion criteria
We identified all adult patients with classical Hodgkin’s disease
(n¼187) followed at our centre (which services a large
metropolitan area with a population of 2.5 million people) between
1990 and 1999 using the centre’s database. We excluded patients
who were diagnosed with Hodgkin’s before January 1st 1990
(n¼10), who were not treated with curative-intent (n¼13), who
failed to respond to initial therapy (n¼3) and those who were not
followed exclusively at our centre for at least 12 months unless this
follow-up was interrupted by death or relapse (n¼54). Follow-up
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ldata were gathered on the remaining 107. Data were censured
when follow-up ceased to be exclusively at our centre.
Follow-up protocol
Patients were assessed every 3 months for the first 2 years after
completion of therapy, every 6 months for years three to five
inclusive, and annually thereafter. Assessments included clinical
assessment (history and physical), a chest X-ray and a complete
blood count. Other radiological testing including computed
tomography (CT) scanning and gallium scanning were left to the
discretion of the investigator.
Outcomes
We defined a suspected relapse as a situation in which a clinical,
radiological or laboratory abnormality prompted an intensification
of follow-up, for example, an additional follow-up visit or an
additional radiological investigation. A true relapse was defined as
a situation in which a biopsy confirmed Hodgkin’s relapse or in
which a radiological finding was sufficient to warrant initiation of
second-line therapy for Hodgkin’s. A false relapse was defined as a
suspected relapse followed by resumption of routine follow-up.
Suspected relapses were attributed to the patient when the
patient expressed concern about a symptom or physical finding
that prompted the physician to depart from the usual follow-up
protocol. The suspected relapse was attributed to the physician’s
assessment when the physician arranged for intensification of
follow-up based on the history or physical exam in the absence of
patient concerns. Suspected relapses were attributed to radiologi-
cal or laboratory testing when abnormal radiological or laboratory
findings, respectively, led to a departure from the follow-up
protocol. In a number of cases, more than one follow-up modality
raised the possibility of relapse. In these cases, the suspected
relapse was attributed to the least invasive modality beginning with
the patient, physician, radiological and finally the laboratory
testing. This hierarchical grading system has been used in a
previous analysis of Hodgkin’s follow-up (Torrey et al, 1997).
The following information was recorded for each patient:
number of follow-up visits, chest X-rays, CT scans, total number
of radiological investigations, number of suspected relapses and
whether a true relapse occurred. For each suspected relapse, the
modality that triggered the intensification of follow-up was
identified and the number of additional follow-up visits and
radiological investigations over and beyond the routine follow-up
protocol were recorded. We calculated the international prognostic
score (IPS) (Hasenclever et al, 1998) for all patients based on the
blood work preceding the onset of therapy most closely. When
blood work was missing (most commonly the pre-therapy
albumin), we calculated the score as though the missing variables
were normal.
The first follow-up visit was defined as the first visit after
completion of therapy. Visits and tests unrelated to potential
Hodgkin’s recurrence were not included. We recorded all
radiological investigations carried out after completion of therapy
to detect relapse. Tests were recorded as routine when there was no
indication in the physician’s notes that a relapse was suspected. On
the other hand, a test was attributed to a suspected relapse (and the
modality that prompted this suspected relapse) when the
physician’s notes indicated that it would not otherwise have been
performed. Once a relapse was suspected, all subsequent
radiological investigations were attributed to that relapse until
the resumption of the usual follow-up regimen. A CT of the chest,
abdomen and pelvis was counted as one CT when performed on
the same day. The ordering of CT scans was not directly limited by
patient or provider financial considerations.
Follow-up information was collected until a biopsy showed
relapse or a radiological finding prompted the initiation of second-
line therapy, the patient died, the patient ceased to follow-up
exclusively at our centre or until the last documented visit and
radiological test.
Cost calculations
The centre cost of clinic visits was derived from the centre’s annual
budget. Physician costs were determined using the provincial
physician fee schedule. Costs of radiological testing were calculated
by adding the professional and radiologist interpretation fees. The
costs of a clinic visit including oncologist fees and the cost of a
complete blood count were US $54, the cost of a chest radiograph
was US $21 and the cost of a CT scan was US $174.
Statistical analysis
Results were analysed using the Statistical Package for the Social
Sciences (SPSS) version 10. The w
2 were used to perform simple
tests of ratio unheterogeneity. Binary logistic regression models
were used to analyse the associations between non-binary factors
and the presence of a true relapse or one or more false relapses.
Linear regression models were used to study the associations
between the number of false relapses and other factors. All P-
values were two-sided. Correlations between factors were analysed
using the Pearson method.
RESULTS
Patient characteristics
Baseline characteristics are summarised in Table 1. A total of 107
patients were included in our analysis, 61 men and 46 women. The
median age was 33 years (range 17–82 years). In all, 54 patients
were excluded because their follow-up was not carried out
Table 1 Characteristics of the 107 patients that met inclusion and
exclusion criteria
Demographics
Median age (range) 33 (17–82)
Male gender 61 (57%)
Ann arbor stage
I 31 (29%)
II 60 (56%)
III 7 (6%)
IV 9 (8%)
B symptoms 27 (25%)
Grade
Nodular sclerosis 66 (62%)
Lymphocyte depletion 1 (1%)
Mixed cellularity 20 (19%)
Lymphocyte rich 20 (19%)
Treatment
Radiotherapy alone 55 (51%)
Combination therapy 34 (32%)
Chemotherapy alone 18 (17%)
International prognostic score
0 23 (21%)
1 49 (46%)
2 23 (21%)
3 8 (8%)
4 2 (2%)
5 2 (2%)
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lexclusively at our centre. This patient group did not differ
significantly from the study population with regard to age and
gender. A total of 51% percent of patients were treated with
radiation alone, 17% with chemotherapy alone and 32% with
combined modality therapy. The chemotherapeutic regimen was
ABVD in 89% of patients. The remainder received MOPP or
MOPP-ABVD.
Follow-up logistics
Follow-up data are summarised is Table 2. The total duration of
follow-up was 4655 patient-months (388 patient-years). The
median duration of follow-up was 38 months (range 1–120
months). The total number of follow-up visits was 1209 (median
11/patient) and the total number of radiological tests was 977
(median 9/patient). Eight haematologists/medical oncologists
and four radiation oncologists were involved in the follow-up
process.
Suspected relapses and true relapses
Figure 1 illustrates the breakdown of the suspected and true
relapses according to detection modality and Figure 2 shows the
breakdown by year. Relapse was suspected in 109 instances
involving 68 patients. Relapse was suspected as a result of patient
concerns in 42%, physician concerns in 26%, radiological findings
in 28% and laboratory abnormalities in 4%. True relapses occurred
in 22 patients. Of these, the largest proportion stemmed from
patient concerns (10), four from physician concerns, six
from radiological abnormalities and two from laboratory abnorm-
alities. Of the six relapses identified radiologically, four stemmed
from a routine chest X-ray and two from a routine CT. Of the 25
false relapses identified radiologically, seven stemmed from a
routine chest X-ray, 12 from a routine CT, five from a routine
gallium scan and one from an ultrasound. The outcomes of routine
clinical, radiological and laboratory investigations are provided in
Table 3.
Factors predicting relapse
Ann Arbor stage IV (OR 8.44; 95% CI 1.57–45.4; P¼0.013) and
therapy other than combined modality treatment (OR 5.88; 95% CI
1.28–25; P¼0.02) were associated with an increased risk of
relapse. Among patients treated with chemotherapy, a higher IPS
was associated with an increased risk of relapse (OR 2.10; 95% CI
1.08–4.07; P¼0.03). The presence of prior suspected relapses did
not affect the likelihood of a true relapse.
Factors predicting the outcome of a suspected relapse
We analysed the settings of all first suspected relapses to determine
which factors predicted the outcome of a suspected relapse. A
suspected relapse was more likely to be a true relapse in patients
treated with radiotherapy alone (OR 5.76; 95% CI 1.14–29.1;
P¼0.03). Age, gender, the presence of B symptoms, Ann Arbor
stage, prognostic score and the time elapsed between the end of
therapy and the suspected relapse did not help distinguish a true
Table 2 Follow-up logistics
Total Median Range
Follow-up duration 4655 months 38 months 1–120 moths
No. of follow-up visits 1209 11 0–31
No. of CXRs 583 5 0–15
No. of CTs 283 2 0–10
No. of radiological investigations 977 9 0–27
This table illustrates the total and median number of visits and radiological
investigations carried out during the follow-up of the 107 patients as well as median
and total duration of follow-up.
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Figure 1 Suspected relapses and true relapses according to modality of
detection. In 109 cases, an abnormality prompted an intensification of
follow-up (suspected relapse) which led to the detection of Hodgkin’s
relapse (true relapse) in 22 cases. Suspected relapses were attributed to
the ‘patient’ (46 cases, yielding 10 relapses) when triggered by a patient-
reported symptom or sign; to the ‘physician’ (28 cases, yielding four
relapses) when triggered by the physical examination; to ‘radiological’ (31
cases, yielding six relapses) when triggered by an abnormality on a CXR, CT
or other radiological investigation; or to ‘laboratory’ (four cases, yielding
two relapses) when brought on by an abnormal CBC. A hierarchical
classification system was employed when multiple follow-up modalities
suggested a possible relapse (see Materials and Methods).
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Figure 2 Suspected relapses and true relapses according to year of
follow-up. This graph illustrates the breakdown by year of follow-up of the
109 suspected relapses, of which 22 were true relapses.
Table 3 Outcomes of routine clinical, radiological and laboratory follow-up
Clinical CXR CT CBC
Routine investigations 1038 544 211 1038
True relapses 14 4 2 2
False relapses 60 7 12 2
This table provides the total number of routine clinical follow-up visits, chest X-rays
(CXR), computed tomography (CT) scans and complete blood counts (CBC). It also
provides the number of true relapses identified by these follow-up modalities as well
as the number of false relapse investigations that they generated. Patient- and
physician-derived relapses were considered jointly. Six of the 109 suspected relapses
were generated by radiological investigations other than CXR or CT (e.g., gallium
scan).
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unhelpful.
Costs
In all, 51% of the total cost of follow-up was attributable to the
visits themselves, 39% to the CT scans and 10% to the chest X-rays
(Figure 3A). The cost per identification of a true relapse was US
$6000. The cost of follow-up was highest during the first year
during which CT scans were responsible for half of the follow-up
expenses (Figure 3B). A total of 84% of the costs of follow-up was
incurred by routine tests, while 15% was due to the investigation of
suspected relapses (Figure 3C). Routine CT scans alone accounted
for 29% of the total cost of follow-up.
DISCUSSION
Our review of follow-up of patients with Hodgkin’s disease after
potentially curative therapy found that (1) two-thirds of relapses
were identified clinically; (2) routine radiological tests identified a
quarter of all relapses, yet accounted for half of the total costs of
follow-up; (3) 211 routine CT scans were performed which
detected only two of 22 relapses, yet accounted for 29% of the
total follow-up costs; (4) for every true relapse identified, four false
relapses were investigated, yet the majority of the cost of follow-up
(84%) was incurred by the cost of routine follow-up; and that (5)
prior treatment with radiotherapy alone made a suspected relapse
more likely to be a true relapse; other factors, including the
modality of the suspected relapse, were unhelpful.
The attribution of suspected relapses to either the patient, the
physician, a radiological investigation or a laboratory value may
not have adequately categorised cases in which a subtle
radiological abnormality, in itself insufficient to drive further
investigations, nevertheless bolstered a physician’s decision to
investigate a clinical symptom. In such a case, the suspec-
ted relapse would be attributed to the patient alone without
reflecting the role played by the radiological abnormality. Our
categorisation of relapses relied mainly on a careful reading of the
physicians’ follow-up visit notes and in the vast majority of cases, a
single modality appeared to trigger a suspected relapse in a
decisive manner. It may also be argued that the hierarchical
grading system that we used biased against radiological investiga-
tions that identified pathology concurrently with the appearance of
clinical symptoms or signs. However, in only one of 22 true
relapses did such a situation occur (the patient reported a
retrosternal ache and the chest X-ray demonstrated a 4cm anterior
mediastinal mass). In addition, only 8% of our patients had Ann
Arbor stage IV disease and only 10% had an IPS of X3. Our results
may therefore be less readily generalised to patients with high-risk
disease.
The relapse rate in this series (21%) is comparable to that found
by Radford et al (18%; Radford et al, 1997) and Torrey et al (22%;
Torrey et al, 1997) in their reviews of Hodgkin’s follow-up. A total
of 64% of relapses in our series were identified clinically,
compared to 69% in the series of Torrey et al. In the series of
Radford et al, 81% of relapses were identified through symp-
toms alone, but the extent of radiological investigations was
limited to a chest X-ray if the patient had mediastinal disease at
presentation. The extent to which radiographs contributed to the
cost of follow-up in our series (49%) is similar to that reported by
Torrey et al (62%). No other series has reported the rates and
modalities of false relapses nor the extent to which CT scans help
detect relapses.
For the exclusive purpose of detecting relapse, it would make
sense to tailor the frequency of follow-up to the likelihood of
relapse based on the treatment modality and the IPS. However, the
follow-up process serves many purposes, including the detection
and management of the late toxicities of therapy and the provision
of psychosocial support. We favour a common follow-up
frequency that provides equal psychosocial support to all
Hodgkin’s patients and is easier to implement logistically. While
some have advocated fewer follow-up visits and more patient
education on the grounds that the identification of most relapses
stem from patient-reported symptoms (Radford et al, 1997), more
than half of the relapses in our series were detected through the
physician’s clinical assessments, radiological investigations or
complete blood counts, all of which require routine visits. Our
experience supports a follow-up frequency based on the Cotswolds
recommendations (Lister et al, 1989).
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Figure 3 (A) Costs of follow-up. This figure illustrates the breakdown of
the costs of follow-up. A total of 51% of the costs were attributable to the
follow-up visits (including the routine CBC), 39% to the CT scans and 10%
to the CXRs. The cost per identification of a true relapse was
approximately US $6000. (B) Costs of the components of follow-up. This
figure illustrates the costs per patient of the follow-up visits, the CXRs and
the CTs for each of the first 6 years of follow-up. A total of 64% of the total
CT costs were incurred during the first year of follow-up, as opposed to
40% of the cost of the follow-up visits. (C) Routine costs vs investigations of
suspected relapse. This figure illustrates the routine costs of follow-up and
the costs of the investigations of suspected relapse for each of the first 6
years of follow-up. Routine follow-up costs amounted to 85% of the total
cost of follow-up.
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of the CT scan is both costly and of little value in the identification
of relapse. The routine CT scan’s ability to generate six times more
false relapses stems from the diagnostic difficulty posed by
residual masses after completion of therapy. Our results argue
that the elimination of routine follow-up CT scans would translate
into a significant reduction in resource utilisation and unnecessary
radiation exposure without compromising the follow-up of
patients with Hodgkin’s disease.
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